LDR’s IPO Bid, FDA Approvals Give Spine Much Needed Adjustment
This article was originally published in The Gray Sheet
Executive Summary
The spine device firm LDR filed to raise up to $69 million in an initial public offering just as it gained FDA approval for its Mobi-C cervical disc for one- and two-level indications. Device investors will keep a close watch on the IPO, which has not been staged by a venture-backed spine startup since 2007.
You may also be interested in...
Cervical Disc Replacement Data Looks Good, But More Needed
Long-term positive outcomes for artificial cervical discs were reported, but the market remains muted by insurance restrictions, and even more data may be needed for a breakthrough.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.